30 closest matches · ranked by relevance
Nephrogenic Systemic Fibrosis
Primary: Percentage Change From Baseline in the Modified Rodnan Skin Score (mRSS) to Assess Skin Tethering — -24 percentage change in mRSS score
Fibrosis · Kidney Failure · Renal Insufficiency
Primary: Number of Participants Who Developed Nephrogenic Systemic Fibrosis (NSF), Based on Diagnostically Specific Clinical and Histopathological Information-cohort Analysis and…
Renal Insufficiency
Primary: Number of Patients With Moderate to Severe Renal Impairment Who Develop Nephrogenic Systemic Fibrosis (NSF) After Administration of Dotarem — 0 Participants
Contrast Media
Primary: Number of Participants With Moderate to Severe Renal Impairment, Who Develop NSF (Nephrogenic Systemic Fibrosis), Based on Diagnostically Specific Clinical and…
Fibrosis · Focal Glomerulosclerosis · Kidney Failure
Primary: Decrease in GFR During Treatment Period — -0.45 ml/min/1.73 m2 — p=<0.01
Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005
Scleroderma, Systemic
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -93.3; -52.4 millilitre (mL)/year (yr) — p=0.0350
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Systemic Sclerosis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 71 Adverse Events
Diabetic Nephropathy
Primary: Ratio to Baseline in Urinary Albumin to Creatinine Ratio (UACR) — 0.90; 1.06; 0.83; 1.00 Ratio to baseline
Nephrogenic Diabetes Insipidus
Primary: 24h Urine Volume — 6475; 4178; 6652; 4188 urine volume in mL/d
Systemic Sclerosis · Scleroderma
Primary: The Benefit That an Antifibrotic Agent and Ambrisentan Combination Have on the Cutaneous Involvement of Patients With Early Diffuse Systemic Sclerosis by Utilizing the…
Chronic Kidney Disease
Primary: Number of Participants With Contrast-induced Acute Kidney Injury — 146; 146 participants
Systemic Sclerosis, Scleroderma
Primary: Change From Baseline in Modified Rodnan Skin Score (MRSS) at Each Time Point of Analysis — 25.7; 6.58; 5.97; 8.34 units on a scale
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Focal Segmental Glomerulosclerosis
Primary: Slope of Estimated Glomerular Filtration Rate (eGFR) — -5.4; -5.7 milliliters/minute/1.73square meter/year — p=0.7491
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Renal Insufficiency
Primary: Number of Patients Presenting Contrast-induced Nephropathy as Defined by an Increase in Serum Creatinine Levels of a Least 25% Over Baseline Levels, in the Full Analysis…
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Skin Score to Week 24 — -2.45; -4.76 score on a scale — p=0.0291
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24 — -9.5 scores on scale
Netherton Syndrome
Primary: Blood Pimecrolimus Levels — 0; 0; 0.312; 1.260 ng/mL
Kidney Diseases
Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day
Alveolitis · Systemic Sclerosis
Primary: Treatment-related Adverse Events — 5 participants
Scleroderma, Systemic
Primary: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) — 8; 3; 24; 1 Participants
Systemic Sclerosis
Primary: Improvement in the Modified Rodnan Skin Score — -6.6 units on a scale
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months
Kidney Failure, Chronic · Kidney Failure, Acute · Heart Failure
Primary: Number of Participants With Acute Kidney Injury During the First 48 Hours After Contrast Administration — 5; 4 Participants
Renal Interstitial Fibrosis
Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants